Delivery Order SPE2DP20D0002-SPE2DP25F055D
- Not listed
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a $146,823.93 firm fixed price delivery order to Teva Pharmaceuticals USA, Inc., a pharmaceutical manufacturer, to provide adenovirus type 4 vaccine. This order supports military immunization programs. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit organization that manufactures a range of drug products, including vaccines, antivirals, respiratory treatments, and multiple sclerosis medications for federal customers...
- Teva Pharmaceuticals USA, Inc. was awarded a Firm Fixed Price Delivery Order by the Defense Logistics Agency Troop Support Medical to provide Adenovirus Type 4 vaccine in Parsippany, New Jersey. The contract has a potential value of $146,823.93 and a completion date of December 20, 2022. Teva is a foreign-owned, for-profit manufacturer that has a history of providing pharmaceutical products, including vaccines and respiratory treatments, to various federal customers such as the Department of...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $476,414.19 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide Adenovirus Type 4 vaccines. This contract, which has a completion date of May 21, 2024, supports military immunization programs. Teva Pharmaceuticals USA, Inc. has a long history of supplying critical pharmaceuticals, including other vaccines and medications, to various federal...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a Firm Fixed Price Delivery Order contract to Teva Pharmaceuticals USA, Inc. for the delivery of Adenovirus Type 4 vaccines. The $135,747.00 contract has an August 25, 2020 completion date. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit manufacturer that has provided a range of pharmaceutical products, including vaccines, antiviral medications, and respiratory treatments, to federal customers such as the Department of...
- Teva Pharmaceuticals USA, Inc. has been awarded a firm fixed price delivery order valued at one hundred fifty-two thousand six hundred ninety-six dollars and eighty-eight cents ($152,696.88) by the Defense Logistics Agency Troop Support Medical to provide adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support immunization programs of the military. Teva Pharmaceuticals USA, Inc. is a manufacturer of pharmaceutical products located in...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a $271,494.00 firm fixed price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned for-profit manufacturer, to provide Adenovirus Type 4 vaccine. This order supports military immunization programs. Teva is an experienced federal contractor, having provided various pharmaceuticals to agencies like the Department of Defense and Department of Veterans Affairs through indefinite delivery contracts. Teva has also been...
- The U.S. Defense Logistics Agency (DLA) awarded Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a $317,609.46 Delivery Order contract for the supply of Adenovirus Type 4 vaccines. This order falls under DLA Troop Support Medical's larger portfolio of contracts supporting military immunization programs. The contract has a firm fixed-price, with a completion date of June 25, 2024. Teva Pharmaceuticals USA, Inc. is a major supplier of critical drugs and...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of Adenovirus Type 4 vaccine, a critical product for military immunization programs. The $158,804.73 firm-fixed-price contract has a period of performance through March 26, 2024. Teva Pharmaceuticals USA, Inc. has been awarded numerous prime federal contracts and delivery orders from...
- SPE2DP20D0002Indefinite Delivery Contract
- SPE2DP20D0002-SPE2DP25F055DDelivery Order
The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to federal healthcare programs, particularly for military immunization initiatives managed through the Defense Logistics Agency Troop Support Medical. Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer and subsidiary of Teva Pharmaceutical Industries Ltd., has demonstrated consistent capability in supplying high-volume essential medical products to federal agencies including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service. The company maintains strategic long-term indefinite delivery contracts with federal agencies valued in the tens of millions of dollars, underscoring its importance to federal pharmaceutical supply chains. This award reflects Teva's qualification as a large business competitor and its reliability in meeting precision delivery requirements for critical healthcare needs across multiple federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2m | 8/12/25 |